Cellectis S.A. (NASDAQ:CLLS) Sees Significant Growth in Short Interest

Cellectis S.A. (NASDAQ:CLLS) saw a large growth in short interest in the month of January. As of January 31st, there was short interest totalling 221,300 shares, a growth of 34.0% from the January 15th total of 165,200 shares. Based on an average daily trading volume, of 139,900 shares, the short-interest ratio is presently 1.6 days.

Cellectis Stock Performance

Cellectis stock traded up $0.02 during mid-day trading on Friday, hitting $1.55. The company had a trading volume of 77,558 shares, compared to its average volume of 167,729. The company has a current ratio of 1.78, a quick ratio of 1.78 and a debt-to-equity ratio of 0.48. Cellectis has a 12-month low of $1.41 and a 12-month high of $3.38. The company’s fifty day moving average is $1.66 and its 200-day moving average is $1.93.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Cellectis stock. Wells Fargo & Company MN increased its holdings in shares of Cellectis S.A. (NASDAQ:CLLS) by 103.4% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 24,590 shares of the biotechnology company’s stock after purchasing an additional 12,500 shares during the quarter. Wells Fargo & Company MN’s holdings in Cellectis were worth $44,000 at the end of the most recent reporting period. 63.90% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms have commented on CLLS. Barclays cut their target price on shares of Cellectis from $7.00 to $5.00 and set an “overweight” rating on the stock in a research report on Tuesday, November 5th. StockNews.com started coverage on shares of Cellectis in a report on Friday, January 24th. They issued a “buy” rating on the stock.

Cellectis Company Profile

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.